{
    "nct_id": "NCT04303780",
    "official_title": "A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C",
    "inclusion_criteria": "* Men or women greater than or equal to 18 years old.\n* ECOG â‰¤ 1\n* Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through central testing or have documentation of KRAS p.G12C mutation through Amgen Study 20190294 prior to enrollment\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Active brain metastases\n* Myocardial infarction within 6 months of study day 1\n* Gastrointestinal (GI) tract disease causing the inability to take oral medication",
    "miscellaneous_criteria": ""
}